Laval, Canada-based Valeant Pharmaceuticals reported a 12.9 percent fall in its fourth quarter revenue, Reuters reports.
Here are three report insights.
1. Valeant's revenues fell 12.9 percent from $2.79 billion to $2.40 billion. The quarter is Valeant's third consecutive quarter of double-digit losses.
2. Valeant's net losses increased to $515 million in Q4.
3. Valeant has been attempting to "rebuild its business and regain investor confidence," after an investigation into its accounting and pricing methods, Reuters reports.